Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial

Reuters03-31

Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial

Innovent partner Ollin Biosciences released final 20-week data from Phase 1b JADE head-to-head study of OLN324 (IBI324) versus Roche’s Vabysmo in diabetic macular edema or wet age-related macular degeneration.
Results showed OLN324 delivered stronger anatomic improvements in diabetic macular edema, with vision gains that held up through follow-up.
Wet age-related macular degeneration data showed comparable fluid control, with a widening edge in vision outcomes for OLN324 by study end.
Newly available anatomic analyses indicated faster, greater, more durable reductions in pigment epithelial detachments versus Vabysmo.
Full data set is expected to be presented at upcoming medical meetings, with global Phase 3 studies planned for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603302000PR_NEWS_USPR_____CN20962) on March 31, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623320255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623320255","market":"nz","top_or_hot":-1,"title":"Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Innovent partner Ollin Biosciences released final 20-week data from Phase 1b JADE head-to-head study of OLN324 (IBI324) versus Roche’s Vabysmo in diabetic macular edema or wet age-related macular degeneration.\n        </li>\n<li>\n          Results showed OLN324 delivered stronger anatomic improvements in diabetic macular edema, with vision gains that held up through follow-up.\n        </li>\n<li>\n          Wet age-related macular degeneration data showed comparable fluid control, with a widening edge in vision outcomes for OLN324 by study end.\n        </li>\n<li>\n          Newly available anatomic analyses indicated faster, greater, more durable reductions in pigment epithelial detachments versus Vabysmo.\n        </li>\n<li>\n          Full data set is expected to be presented at upcoming medical meetings, with global Phase 3 studies planned for 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603302000PR_NEWS_USPR_____CN20962) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-31 08:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Innovent partner Ollin Biosciences released final 20-week data from Phase 1b JADE head-to-head study of OLN324 (IBI324) versus Roche’s Vabysmo in diabetic macular edema or wet age-related macular degeneration.\n        </li>\n<li>\n          Results showed OLN324 delivered stronger anatomic improvements in diabetic macular edema, with vision gains that held up through follow-up.\n        </li>\n<li>\n          Wet age-related macular degeneration data showed comparable fluid control, with a widening edge in vision outcomes for OLN324 by study end.\n        </li>\n<li>\n          Newly available anatomic analyses indicated faster, greater, more durable reductions in pigment epithelial detachments versus Vabysmo.\n        </li>\n<li>\n          Full data set is expected to be presented at upcoming medical meetings, with global Phase 3 studies planned for 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603302000PR_NEWS_USPR_____CN20962) on March 31, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828557.USD","symbol_name":"AZ EQUITY CHINA \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL9qWvky:1","article_id":"2623320255","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623320255","pubTimestamp":1774915229,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innovent partner Ollin Biosciences released final 20-week data from Phase 1b JADE head-to-head study of OLN324  versus Roche’s Vabysmo in diabetic macular edema or wet age-related macular degeneration.Results showed OLN324 delivered stronger anatomic improvements in diabetic macular edema, with vision gains that held up through follow-up.Wet age-related macular degeneration data showed comparable fluid control, with a widening edge in vision outcomes for OLN324 by study end.Newly available anatomic analyses indicated faster, greater, more durable reductions in pigment epithelial detachments versus Vabysmo.Full data set is expected to be presented at upcoming medical meetings, with global Phase 3 studies planned for 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","01801":"信达生物","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","BK1583":"高瓴概念","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","BK1589":"北水核心资产","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK1147":"投资银行业与经纪业","BK1161":"生物科技","01911":"华兴资本控股","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A"},"translate_title":"信达生物合作伙伴奥铃称OLN324在1b期试验中在DME解剖方面击败了罗氏的Vabysmo","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01911":0.9,"01801":0.9},"content_text":"Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial\n    \n\n\n          Innovent partner Ollin Biosciences released final 20-week data from Phase 1b JADE head-to-head study of OLN324 (IBI324) versus Roche’s Vabysmo in diabetic macular edema or wet age-related macular degeneration.\n        \n\n          Results showed OLN324 delivered stronger anatomic improvements in diabetic macular edema, with vision gains that held up through follow-up.\n        \n\n          Wet age-related macular degeneration data showed comparable fluid control, with a widening edge in vision outcomes for OLN324 by study end.\n        \n\n          Newly available anatomic analyses indicated faster, greater, more durable reductions in pigment epithelial detachments versus Vabysmo.\n        \n\n          Full data set is expected to be presented at upcoming medical meetings, with global Phase 3 studies planned for 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603302000PR_NEWS_USPR_____CN20962) on March 31, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623320255","isCrawlerRequest":true}